Patent ductus arteriosus

Patent ductus arteriosus (PDA) is a congenital cardiac anomaly characterized by the persistent patency of the ductus arteriosus after birth. It represents one of the most common forms of acyanotic congenital heart disease and plays a crucial role in neonatal and pediatric cardiology due to its hemodynamic implications and treatable nature.

Introduction

Definition of Patent Ductus Arteriosus (PDA)

Patent ductus arteriosus refers to the failure of closure of the ductus arteriosus, a normal fetal vascular connection between the pulmonary artery and the descending aorta. Persistence of this connection after birth allows abnormal blood flow from the aorta to the pulmonary artery, leading to a left-to-right shunt and increased pulmonary blood flow.

Embryological Basis

The ductus arteriosus develops from the distal portion of the left sixth aortic arch during fetal life. It plays a vital role in diverting blood away from the non-functioning fetal lungs by connecting the pulmonary artery to the aorta. Normally, it closes functionally within the first 24 to 48 hours after birth and anatomically within two to three weeks. Failure of closure results in a patent ductus arteriosus.

Historical Background

The first clinical description of PDA was provided in the 19th century, and surgical correction was first successfully performed by Dr. Robert E. Gross in 1938. Since then, treatment modalities have evolved significantly, including pharmacologic closure using prostaglandin inhibitors and transcatheter occlusion techniques.

Epidemiology and Prevalence

PDA accounts for approximately 5–10% of all congenital heart defects. It is more frequent in premature infants and females. The incidence is higher in neonates born at high altitudes and in those with maternal infections, particularly rubella, during pregnancy. Advances in neonatal intensive care have improved the recognition and management of PDA, especially in preterm populations.

Anatomy and Embryology

Normal Fetal Circulation

During fetal life, the lungs are non-functional, and oxygenation occurs through the placenta. The ductus arteriosus serves as a crucial shunt that diverts blood from the pulmonary artery directly into the aorta, bypassing the lungs. This ensures adequate systemic circulation and oxygen delivery to vital organs.

Structure and Location of the Ductus Arteriosus

The ductus arteriosus is a short, wide vessel located between the left pulmonary artery and the descending aorta, just distal to the origin of the left subclavian artery. Its wall is composed of smooth muscle and elastic tissue, which are highly sensitive to oxygen tension and circulating prostaglandins.

Physiological Role During Fetal Life

The ductus arteriosus allows most of the right ventricular output to bypass the pulmonary circulation and enter the systemic circuit. This arrangement ensures that oxygenated blood from the placenta is distributed to the brain and heart, maintaining fetal metabolic demands.

Normal Closure Mechanism After Birth

At birth, the onset of respiration increases oxygen concentration and reduces circulating prostaglandin E₂ levels, leading to constriction of the ductal smooth muscle. Functional closure occurs within 1–2 days, followed by fibrous remodeling that converts the ductus into the ligamentum arteriosum within several weeks. Premature infants often have delayed closure due to persistent prostaglandin sensitivity.

Embryological Basis of Persistent Patency

Persistent patency of the ductus arteriosus may result from structural immaturity, defective smooth muscle contraction, or abnormal prostaglandin metabolism. Genetic and environmental factors can interfere with the normal closure mechanisms, leading to continued communication between the pulmonary and systemic circulations after birth.

Pathophysiology

Hemodynamic Changes in PDA

In patent ductus arteriosus, the persistence of the ductus creates an abnormal communication between the systemic and pulmonary circulations. Due to higher systemic pressure in the aorta compared to the pulmonary artery, blood flows from the aorta to the pulmonary artery, resulting in a left-to-right shunt. The magnitude of this shunt depends on the size of the ductus and the pressure gradient between the two vessels.

Left-to-Right Shunt Mechanism

The left-to-right shunt increases pulmonary blood flow and venous return to the left atrium and ventricle. Over time, this leads to volume overload in the left side of the heart, progressive cardiac dilation, and increased workload on the left ventricle. This compensatory response may initially maintain cardiac output but eventually contributes to heart failure if untreated.

Effects on Pulmonary Circulation

Increased pulmonary flow causes elevation of pulmonary vascular pressures and endothelial injury. Chronic exposure to high flow may lead to structural remodeling of the pulmonary vessels, including medial hypertrophy and intimal fibrosis. Persistent pulmonary hypertension can eventually reverse the direction of the shunt, producing a right-to-left flow characteristic of Eisenmenger syndrome.

Changes in Cardiac Output and Ventricular Function

In the presence of PDA, left ventricular preload is elevated due to increased venous return, while systemic cardiac output decreases as part of it is diverted to the pulmonary circulation. Over time, ventricular hypertrophy and decreased compliance develop, leading to reduced systolic efficiency and symptoms of congestive heart failure.

Progression to Pulmonary Hypertension and Eisenmenger Syndrome

If the PDA remains untreated, prolonged pulmonary overcirculation results in irreversible vascular remodeling and pulmonary hypertension. As pulmonary vascular resistance exceeds systemic resistance, shunt reversal occurs, leading to cyanosis, clubbing, and secondary erythrocytosis. This stage, known as Eisenmenger syndrome, represents the terminal phase of the disease and is often inoperable.

Etiology and Risk Factors

Genetic and Chromosomal Factors

Genetic predisposition plays a role in the occurrence of PDA, with an increased incidence in individuals with chromosomal abnormalities such as trisomy 21 (Down syndrome), trisomy 13, and trisomy 18. Familial clustering and certain genetic syndromes, including Char syndrome, are also associated with ductal patency.

Prematurity and Low Birth Weight

Premature infants are particularly susceptible to PDA due to immature ductal smooth muscle and heightened sensitivity to prostaglandins. The incidence of PDA increases inversely with gestational age, with rates as high as 60% in neonates born before 28 weeks. Low birth weight further compounds the risk by affecting vascular reactivity and oxygen response mechanisms.

Maternal Rubella Infection

Maternal rubella during the first trimester of pregnancy is a well-known cause of PDA. The rubella virus interferes with normal vascular development and ductal closure mechanisms in the fetus. The condition often occurs in conjunction with other cardiac anomalies such as pulmonary artery stenosis or septal defects.

High Altitude Births

Infants born at high altitudes have an increased risk of PDA due to relative hypoxia, which delays the normal constriction of the ductus arteriosus. Reduced oxygen tension maintains prostaglandin-mediated vasodilation, leading to persistent patency after birth.

Drug Exposure During Pregnancy

Certain medications taken during pregnancy can predispose to PDA. Maternal use of anticonvulsants such as phenytoin, or drugs affecting prostaglandin metabolism, can interfere with normal ductal closure. Conversely, antenatal administration of prostaglandin inhibitors like indomethacin may cause premature ductal constriction in utero.

Association with Other Congenital Heart Defects

PDA may occur as an isolated defect or in association with other congenital heart diseases such as coarctation of the aorta, ventricular septal defect, or transposition of the great arteries. In complex congenital malformations, the ductus may remain open to sustain systemic or pulmonary circulation until definitive surgical correction is performed.

Classification

Based on Size of Ductus

• Small PDA: Usually asymptomatic and often detected incidentally. The shunt volume is minimal, with no significant cardiac enlargement or pulmonary hypertension.
• Moderate PDA: Produces an audible murmur, mild left heart enlargement, and occasionally signs of early pulmonary overcirculation.
• Large PDA: Associated with significant left-to-right shunt, marked cardiac dilation, and risk of congestive heart failure and pulmonary hypertension if untreated.

Based on Hemodynamic Significance

• Insignificant PDA: Small ductus with no detectable symptoms or cardiac strain.
• Hemodynamically Significant PDA: Causes measurable changes in pulmonary and systemic circulation pressures, with evidence of volume overload or clinical symptoms.

Based on Direction of Shunt

• Left-to-Right Shunt: The most common type, occurring due to higher systemic pressure, leading to pulmonary overcirculation.
• Right-to-Left Shunt: Occurs in advanced cases with severe pulmonary hypertension, indicating Eisenmenger physiology.

Clinical and Functional Grading

Clinicians may classify PDA based on functional impact:

• Silent PDA: Detected incidentally on echocardiography with no clinical manifestations.
• Audible PDA: Presents with a characteristic continuous “machinery” murmur but minimal symptoms.
• Symptomatic PDA: Demonstrates overt signs of heart failure, pulmonary congestion, and failure to thrive in infants.

Clinical Features

Symptoms in Infants and Children

The clinical presentation depends on the ductal size and the magnitude of the shunt. Small PDAs may be asymptomatic, whereas larger ones cause noticeable symptoms. Common manifestations include:

• Poor feeding and failure to thrive
• Tachypnea and dyspnea, especially during exertion or feeding
• Recurrent respiratory infections due to pulmonary congestion
• Fatigue and poor weight gain

Symptoms in Adults

Adults with untreated PDA may present with exertional dyspnea, palpitations, or signs of heart failure. Long-standing PDA can lead to progressive pulmonary hypertension, cyanosis, and clubbing due to shunt reversal. In rare cases, infective endarteritis may be the first clinical manifestation.

Signs on Physical Examination

• Characteristic Murmur: A continuous “machinery” murmur best heard at the left upper sternal border, often radiating to the back or clavicle.
• Bounding Pulse and Wide Pulse Pressure: Resulting from runoff of blood from the aorta into the pulmonary circulation during diastole.
• Cardiac Enlargement: Palpable left ventricular impulse due to volume overload.
• In severe cases: Signs of pulmonary congestion or right heart failure may be evident.

Complications of Untreated PDA

• Pulmonary hypertension and right ventricular hypertrophy
• Congestive heart failure
• Infective endocarditis or endarteritis
• Eisenmenger syndrome with shunt reversal
• Arrhythmias due to atrial or ventricular dilation

The clinical spectrum of PDA varies widely—from asymptomatic cases requiring observation to severe forms necessitating urgent closure. Early recognition through clinical and diagnostic evaluation remains key to preventing long-term complications.

Diagnostic Evaluation

History and Physical Examination

Diagnosis of patent ductus arteriosus begins with a thorough clinical evaluation. A history of prematurity, maternal rubella infection, or persistent respiratory distress in neonates may suggest PDA. Physical examination often reveals a continuous “machinery” murmur, bounding peripheral pulses, and signs of left heart volume overload in moderate to large defects.

Cardiac Auscultation Findings

The hallmark auscultatory finding is a continuous murmur best heard in the left second intercostal space, radiating toward the left clavicle or back. The murmur is accentuated during systole and fades slightly in diastole. In large shunts, additional findings may include a palpable thrill and hyperdynamic precordium.

Chest X-Ray Findings

Radiographic examination may show cardiomegaly with prominence of the left atrium and ventricle. Pulmonary vascular markings are often increased due to overcirculation. In long-standing cases, signs of pulmonary hypertension such as pruning of distal pulmonary vessels may appear.

Electrocardiogram (ECG) Findings

The ECG in small PDAs may be normal, whereas larger defects exhibit evidence of left atrial and left ventricular hypertrophy. In advanced cases with pulmonary hypertension, right ventricular hypertrophy and right axis deviation may develop.

Echocardiography

Two-dimensional and Doppler echocardiography are the primary diagnostic modalities for PDA. Echocardiography identifies the ductus, measures its diameter, and quantifies the direction and magnitude of shunting. Color Doppler imaging visualizes continuous flow between the aorta and pulmonary artery. Additionally, left atrial and ventricular enlargement may be documented, correlating with hemodynamic burden.

Cardiac Catheterization and Angiography

Cardiac catheterization is used to confirm diagnosis and measure pulmonary and systemic pressures, especially when non-invasive imaging is inconclusive. It also assists in assessing operability in patients with elevated pulmonary vascular resistance. Angiographic visualization delineates ductal anatomy and is essential for planning transcatheter closure procedures.

Advanced Imaging

Computed tomography (CT) and magnetic resonance imaging (MRI) provide high-resolution visualization of ductal anatomy, especially in adults or complex congenital cases. These modalities are valuable when evaluating postoperative outcomes or associated vascular anomalies.

Hemodynamic Consequences

Effect on Left Heart Chambers

The left atrium and left ventricle experience chronic volume overload due to the recirculation of blood through the pulmonary circuit. This leads to chamber dilation, increased wall stress, and progressive hypertrophy. Over time, the left ventricular ejection fraction may decline, resulting in systolic dysfunction and symptoms of congestive heart failure.

Effect on Pulmonary Artery Pressure

Increased blood flow through the pulmonary artery elevates pulmonary arterial pressure. Persistent high flow triggers vascular remodeling, with hypertrophy and fibrosis of the pulmonary arterioles. This gradually increases pulmonary vascular resistance, predisposing to pulmonary hypertension and eventual reversal of the shunt.

Impact on Systemic Circulation

Systemic diastolic pressure falls due to runoff of blood from the aorta into the pulmonary circulation, producing a widened pulse pressure. This leads to bounding pulses, which are characteristic of PDA. Systemic perfusion may be compromised in severe cases, contributing to fatigue, failure to thrive, or exercise intolerance.

Chronic Changes Leading to Eisenmenger Physiology

Chronic overcirculation of the pulmonary vasculature leads to irreversible vascular injury and increased pulmonary resistance. Once pulmonary pressure exceeds systemic levels, the direction of shunting reverses, resulting in right-to-left flow. This causes systemic desaturation, cyanosis, and clubbing, marking the development of Eisenmenger physiology—a stage where surgical or interventional closure is contraindicated due to the risk of right ventricular failure.

The hemodynamic profile of PDA evolves with time, transitioning from a benign left-to-right shunt in early life to complex circulatory compromise in advanced, untreated cases. Understanding these changes is essential for timely intervention and prevention of irreversible complications.

Management

Medical Management

Medical therapy is primarily indicated for premature infants in whom spontaneous ductal closure has not occurred. The goal of treatment is to promote functional and anatomical closure of the ductus arteriosus while minimizing complications. Pharmacologic closure is achieved through the inhibition of prostaglandin synthesis, which reduces ductal smooth muscle relaxation and promotes constriction.

• Prostaglandin Inhibitors: Indomethacin and ibuprofen are the most commonly used agents for PDA closure in neonates. These nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase, thereby reducing prostaglandin E₂ levels. Both medications are effective in closing the ductus in approximately 70–90% of cases.
• Acetaminophen: In cases where indomethacin or ibuprofen is contraindicated, acetaminophen may be used as an alternative mechanism for inhibiting prostaglandin synthesis.
• Fluid and Oxygen Management: Limiting fluid overload and optimizing oxygenation are critical in reducing pulmonary congestion. Supplemental oxygen may aid ductal constriction by enhancing oxygen tension in the blood.
• Monitoring and Follow-Up: Serial echocardiography is used to assess closure status and monitor for potential complications such as renal dysfunction or gastrointestinal bleeding associated with NSAID use.

Management of Complications

In infants with heart failure symptoms secondary to large PDAs, diuretics such as furosemide may be administered to control pulmonary congestion. Digitalis therapy is rarely required but may be considered in severe cases of left ventricular dysfunction. Medical therapy is generally a temporary measure until definitive closure is achieved.

Interventional and Surgical Management

Definitive management involves closure of the PDA to prevent hemodynamic overload and long-term complications. The choice between transcatheter intervention and surgical ligation depends on patient age, ductal anatomy, and availability of expertise.

Catheter-Based Closure Devices

Transcatheter closure is the preferred method for older infants, children, and adults with suitable ductal anatomy. Various occlusion devices such as coils, Amplatzer duct occluders, or vascular plugs are deployed through cardiac catheterization. These procedures have high success rates with minimal complications and shorter hospital stays compared to open surgery.

Surgical Ligation Techniques

In neonates, premature infants, or those with large or tortuous PDAs unsuitable for catheter closure, surgical ligation remains the treatment of choice. The procedure involves thoracotomy and division or clipping of the ductus arteriosus. Surgical outcomes are excellent, with very low recurrence rates and minimal postoperative complications when performed by experienced teams.

Postoperative Care and Follow-Up

Following closure, patients are monitored for residual shunts, bleeding, or infection. Echocardiography is performed post-procedure to confirm complete occlusion. Long-term follow-up is essential to monitor cardiac function and ensure no recurrence of ductal flow. Endocarditis prophylaxis may be recommended for several months after closure.

Prognosis and Outcomes

Prognosis After Closure

The prognosis of patients with PDA is excellent following successful closure. Early intervention prevents irreversible pulmonary vascular disease and normalizes cardiac function. Most patients experience complete recovery with normal exercise tolerance and life expectancy comparable to the general population.

Long-Term Cardiac Function

After closure, left ventricular volume overload resolves gradually as the cardiac chambers remodel. Ventricular function typically normalizes within weeks to months. In adults with delayed repair, mild residual left ventricular dilation or diastolic dysfunction may persist, though clinically insignificant in most cases.

Potential Complications Post-Treatment

• Residual or recurrent shunt due to incomplete closure
• Device embolization (rare in transcatheter procedures)
• Injury to adjacent structures such as the recurrent laryngeal nerve during surgery
• Transient arrhythmias or bleeding postoperatively

Quality of Life and Survival Rates

Children and adults with successfully treated PDA typically lead normal, active lives without activity restrictions. Survival rates approach 100% in patients treated before the onset of pulmonary hypertension. Early detection and intervention have markedly improved long-term outcomes, transforming PDA from a potentially life-threatening condition into a curable congenital defect.

Complications

Pulmonary Hypertension

Chronic exposure of the pulmonary vasculature to high pressure and flow due to a left-to-right shunt leads to pulmonary vascular remodeling. Over time, the pulmonary arteries develop medial hypertrophy and intimal fibrosis, resulting in increased vascular resistance. If left untreated, this progression culminates in pulmonary hypertension, which may become irreversible and severely limit surgical correction options.

Eisenmenger Syndrome

In advanced stages of PDA with uncorrected pulmonary hypertension, the shunt direction may reverse, allowing deoxygenated blood to flow from the pulmonary artery into the aorta. This reversal causes systemic desaturation, cyanosis, and digital clubbing. Eisenmenger syndrome marks the end-stage of the condition, and once established, closure of the ductus is contraindicated due to the risk of right heart failure.

Congestive Heart Failure

Significant left-to-right shunting results in chronic volume overload of the left heart chambers. This increased workload causes ventricular dilation, reduced contractility, and ultimately congestive heart failure. Symptoms include tachypnea, hepatomegaly, fatigue, and failure to thrive in infants. Early closure of the PDA effectively prevents these complications.

Endocarditis and Endarteritis

Patients with untreated PDA are at increased risk of bacterial infection along the endothelial lining of the ductus arteriosus or nearby vessels. Infective endarteritis may present with fever, malaise, or embolic phenomena and can lead to serious complications such as sepsis or rupture. Prophylactic measures and timely closure are crucial to prevent this potentially fatal condition.

Arrhythmias and Left Heart Enlargement

Prolonged cardiac volume overload can lead to atrial and ventricular enlargement, predisposing patients to atrial fibrillation or other supraventricular arrhythmias. These rhythm disturbances may exacerbate cardiac dysfunction and require long-term monitoring even after defect closure.

Recognizing and addressing these complications early in the disease course is essential to prevent irreversible cardiac or vascular damage. Timely management significantly improves prognosis and reduces morbidity.

Prevention

Prenatal Care and Maternal Health

Preventive strategies for PDA begin with optimal maternal health during pregnancy. Routine prenatal care, including management of maternal infections and avoidance of harmful drug exposures, reduces the risk of congenital heart defects. Maintaining adequate oxygenation and avoiding premature delivery are also essential in minimizing the risk of PDA in neonates.

Rubella Immunization

Congenital rubella syndrome remains a well-established cause of PDA. Universal vaccination of women of childbearing age against rubella has significantly reduced its incidence. Immunization prior to conception prevents maternal-fetal transmission of the virus and associated cardiac malformations.

Prevention in Preterm Infants

In premature infants, PDA can be prevented or minimized by strategies that reduce prostaglandin-mediated ductal patency. The administration of prophylactic indomethacin or ibuprofen in high-risk preterm neonates has been shown to decrease the incidence of symptomatic PDA. Proper respiratory management and judicious oxygen therapy also aid in facilitating natural ductal closure.

Screening and Early Diagnosis in High-Risk Groups

Early screening using echocardiography in premature or low-birth-weight infants enables prompt detection and intervention before complications arise. High-risk neonates with persistent murmurs or respiratory distress should undergo early evaluation for PDA. Awareness among healthcare providers ensures timely referral and management, reducing long-term sequelae.

Overall, prevention of PDA relies on maternal immunization, avoidance of teratogenic exposures, and proactive neonatal screening. These measures have significantly lowered the global incidence of PDA and improved neonatal outcomes through early identification and management.

Recent Advances and Research

New Device Technologies for PDA Closure

Recent innovations in device engineering have revolutionized the transcatheter closure of patent ductus arteriosus. The introduction of advanced occluders such as the Amplatzer Duct Occluder II, Nit-Occlud coils, and biodegradable polymer-based plugs has improved success rates while minimizing complications. These devices are designed for precise deployment, enhanced conformability to ductal anatomy, and reduced risk of embolization. Miniaturized delivery systems have expanded treatment possibilities for preterm infants and neonates who were previously considered unsuitable for catheter-based closure.

Advances in Minimally Invasive Procedures

Modern interventional cardiology has shifted toward minimally invasive, percutaneous techniques that avoid thoracotomy and general anesthesia. The use of high-resolution fluoroscopy and real-time echocardiographic guidance allows for accurate device placement and immediate verification of closure. These advancements have led to shorter recovery times, reduced postoperative pain, and faster discharge, making transcatheter PDA closure the preferred standard of care in most centers.

Pharmacogenetic Insights into Prostaglandin Metabolism

Recent research has identified genetic variations that influence the response to prostaglandin inhibitors used for medical PDA closure. Genes related to cyclooxygenase and prostaglandin receptor pathways may predict the efficacy of drugs such as indomethacin and ibuprofen in preterm infants. Pharmacogenetic screening could allow clinicians to personalize therapy, selecting the most effective agent while reducing the risk of adverse effects.

Long-Term Outcomes in Extremely Low Birth Weight Infants

Studies focusing on extremely low birth weight (ELBW) infants have demonstrated that early detection and timely management of PDA significantly improve neurodevelopmental and respiratory outcomes. Novel strategies involving gentle pharmacologic closure, targeted echocardiographic surveillance, and selective intervention have reduced morbidity without compromising long-term growth and survival. Ongoing trials continue to refine the timing and indications for intervention in this vulnerable population.

Overall, these advances in technology, genetics, and clinical strategy continue to optimize PDA management, moving toward safer, more individualized, and less invasive care pathways.

Clinical Significance of Early Detection and Treatment

Early identification of PDA through newborn screening and echocardiography allows for prompt intervention before irreversible cardiovascular changes develop. Appropriate management prevents progressive pulmonary hypertension and preserves normal cardiac function. Early closure is particularly crucial in preterm infants, where PDA contributes significantly to respiratory and hemodynamic instability.

Future Directions in PDA Research and Management

Future research aims to further refine minimally invasive closure techniques and integrate artificial intelligence into echocardiographic evaluation for improved diagnostic precision. The development of fully biodegradable occlusion devices and gene-guided pharmacologic therapies holds promise for safer and more targeted interventions. Continued collaboration between neonatologists, cardiologists, and biomedical engineers will enhance outcomes and reduce the global burden of PDA.

In conclusion, patent ductus arteriosus represents a well-understood and effectively treatable congenital condition. Advances in diagnostic imaging, interventional cardiology, and pharmacogenetics have transformed its management, offering patients rapid recovery, long-term cardiac health, and an excellent quality of life.

References

1. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation. 2006;114(17):1873–1882.
2. Glatz AC, Shah SS, McCarthy AL, Owens ST. Management of patent ductus arteriosus in term infants. Pediatr Cardiol. 2011;32(8):1231–1240.
3. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: Time to accept the null hypothesis? J Perinatol. 2010;30(4):241–252.
4. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010;125(5):1020–1030.
5. Gross RE, Hubbard JP. Surgical ligation of a patent ductus arteriosus: Report of the first successful case. JAMA. 1939;112(8):729–731.
6. Brady KM, Polin RA. Patent ductus arteriosus. In: Gleason CA, Juul SE, editors. Avery’s Diseases of the Newborn. 11th ed. Philadelphia: Elsevier; 2024. p. 835–845.
7. Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Patent ductus arteriosus in preterm infants: Do we have the right answers? BioMed Res Int. 2013;2013:676192.
8. Krichenko A, Benson LN, Burrows P, Möes CA, McLaughlin P, Freedom RM. Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol. 1989;63(12):877–880.
9. Rudolph AM. Congenital Diseases of the Heart: Clinical-Physiological Considerations. 3rd ed. Hoboken: Wiley-Blackwell; 2016.
10. American Heart Association. Guidelines for the management of congenital heart disease in adults: Patent ductus arteriosus section. Circulation. 2018;138(15):e698–e800.